Transcatheter implantation of SAPIEN 3 valve in native right ventricular outflow tract for severe pulmonary regurgitation following tetralogy of fallot repair

详细信息    查看全文

• 作者：Toby Rockefeller ; Shabana Shahanavaz ; Alan Zajarias and David Balzer
• 刊名：Catheterization and Cardiovascular Interventions
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：88
• 期：1
• 页码：E28-E33
• 全文大小：343K
• ISSN：1522-726X

文摘

Pulmonary valve replacement (PVR) is indicated in patients with significant pulmonary regurgitation (PR), stenosis (PS), or mixed pulmonary valve disease. While once an exclusively surgical procedure, many patients can undergo transcatheter PVR (TPVR) with excellent early outcomes (Haas et al. 2013, Clin. Res. Cardiol. Off. J. German Cardiac Soc. 102:119–128; Kenny et al. 2011, J. Am. Coll. Cardiol. 58:2248–2256; Cheatham et al. Circulation 2015, 131:1960–1970). The available transcatheter options continue to expand, but the majority of cases performed in the United States involve the use of FDA approved Melody valve (Medtronic; Minneapolis, MN) or the SAPIEN (Edwards Lifesciences; Irvine, CA) family of valves. The SAPIEN 3 valve (S3) recently received FDA approval for transcatheter aortic valve replacement. We report the first S3 implantation in the pulmonary position for treatment of chronic pulmonary regurgitation and progressive right ventricular dilation in an 18 year old male with repaired Tetralogy of Fallot.